Maxtel

Quick links to important sections

Maxtel

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Maxtel

Quick Facts

Property Description
Active ingredient Telmisartan
Form Oral Tablet
Pharmacological class Angiotensin II Receptor Blocker (ARB) / Sartan
General purpose Antihypertensive agent
Origin Synthetic (Non-peptide)

What Type of Medicine is Maxtel (Telmisartan)?

Maxtel is a synthetic, prescription-only medicinal product used as an antihypertensive agent to help regulate blood pressure. Its active chemical compound is Telmisartan (the International Nonproprietary Name or INN), which belongs to the pharmacological class known as Angiotensin II Receptor Blockers (ARBs), sometimes referred to as Sartans. This classification establishes that Maxtel works specifically by interacting with the body's natural system for controlling vascular tone, representing a highly targeted approach to managing systemic vascular resistance.


Composition, Form, and Origin of Maxtel

The sole therapeutic agent in Maxtel is Telmisartan, presented as a single-ingredient product in the dosage form of an oral tablet. Telmisartan is a non-peptide chemical synthesized in a laboratory, classifying its origin as synthetic. The structure of Telmisartan is recognized for having high affinity for the AT1 receptor. A unique pharmacological feature of Telmisartan is its relatively long elimination half-life, a characteristic that supports its use in achieving stable, once-daily dosing for the patient. The tablet is designed for efficient absorption following oral administration, utilizing solid excipients as a necessary base to deliver the active substance effectively throughout the body for systemic effect.


How Does Maxtel Generally Help the Body?

Maxtel's general purpose is to promote the lowering of elevated blood pressure by addressing the signals that cause blood vessels to tighten. The medication achieves this by selectively blocking the action of a natural hormone called Angiotensin II at its primary receptor site. This targeted blockade relaxes and widens the blood vessels, reducing overall resistance and making it easier for the heart to pump blood. The resulting sustained lowering of blood pressure is the primary general benefit of this medication, serving its core function as an antihypertensive agent.

Regulatory References

  1. National Institutes of Health

What side effects are possible with Maxtel?

The official safety profile of Maxtel (Telmisartan) details potential adverse reactions based on their frequency of occurrence in controlled clinical trials and post-marketing surveillance, as defined by government regulatory standards.

Officially Classified Side Effects

Adverse reactions are grouped by System-Organ Class and frequency:

  • Common (ge 1/100 to <1/10): Back pain, sinusitis, and diarrhea are among the most frequently reported events.
  • Uncommon (ge 1/1,000 to <1/100): This category includes events such as anaemia (Blood and Lymphatic System disorders), hyperkalemia (Metabolism), hypotension (Vascular disorders), syncope, and renal impairment, which can progress to acute renal failure.
  • Rare (ge 1/10,000 to <1/1,000): Rare events include serious conditions such as sepsis (blood poisoning, also reported with fatal outcome) and angioedema (swelling of the face, limbs, or throat, also reported with fatal outcome).

Population-Specific Safety Constraints

The label defines specific limitations for certain groups:

  • Pregnancy: Use during the second and third trimesters is contraindicated due to the risk of fetal and neonatal injury, including renal failure and death.
  • Hepatic Impairment: The medication is contraindicated in severe hepatic impairment, cholestasis, or biliary obstructive disorders.
  • Diabetic Patients: There is a documented increased risk of hypoglycemia when Telmisartan is used alongside concurrent insulin or other antidiabetic agents.

High-Level Safety Restrictions

Symptomatic hypotension, low blood pressure, is noted as a safety pattern that may occur, particularly after the first dose, in patients who are volume- or salt-depleted. Additionally, the label notes that concomitant use with other agents that block the Renin-Angiotensin-Aldosterone System (Dual RAS Blockade) is associated with increased risks of hypotension, hyperkalemia, and worsening renal function.

Overdose and Emergency Response

Overdose and when to seek help

The official overdose information for Maxtel (Telmisartan) documents that the most likely manifestation of excessive exposure is hypotension (low blood pressure), often accompanied by dizziness. Cardiovascular signs may include both a fast heart rate (tachycardia) or a slow heart rate (bradycardia), with the latter sometimes resulting from parasympathetic, or vagal, stimulation. The effects on the cardiovascular system are the primary documented concern.

Immediate medical attention is mandatory if severe outcomes are observed. Urgent contact with emergency services must be made if an individual experiences collapse, a seizure, trouble breathing, or cannot be awakened. If symptomatic hypotension is observed, the regulatory guidance states that supportive treatment should be instituted immediately by a medical professional to stabilize the condition.

Overdose is classified as severe given the risk of these life-threatening events. The official profile for management notes that Telmisartan is not removed by hemodialysis, a critical finding that guides clinical observation and procedural planning in a hospital setting. No specific chemical antidote is described in the regulatory documentation for this type of exposure.

Therapeutic Uses of Maxtel

What Maxtel Treats: Main Uses and Benefits

Maxtel is used in situations involving certain distressing symptoms related to cardiovascular health. As such, the medication is relevant for easing symptoms related to systemic imbalance and maintaining functional stability.

This medication is commonly used to help with the sustained management of elevated blood pressure, across conditions presenting with episodic or fluctuating manifestations, and for the supportive care of conditions where functional stability becomes affected.

Therapeutic Benefits and Clinical Scenarios

Maxtel is commonly used to help with the sustained management of elevated blood pressure, a condition presenting with systemic or localized discomfort. It plays a role in managing symptoms related to systemic imbalance, which may assist with maintaining functional stability. This provides supportive relief when symptoms interfere with routine activities. It is considered relevant in clinical settings that involve acute or unstable symptom patterns, and helps address symptom clusters that may become intense or disruptive.

In patients with established heart failure, Maxtel assists with managing symptoms related to physical discomfort, such as fluid retention and breathlessness, which may interfere with daily functioning. This use supports general well-being during symptomatic phases.

Quick Fact: Support for Symptom Management
Maxtel helps address symptom clusters that may become intense or disruptive and assists with maintaining functional stability.

Regulatory References

  1. National Institutes of Health (NIH) on ACE Inhibitors

Eligibility and Restrictions for Use

Maxtel (Telmisartan) eligibility is defined by regulatory bodies through specific contraindications and population restrictions.

Populations for Whom Use is Contraindicated

Maxtel must not be used by the following groups, as stated in official labeling:

  • Patients with known hypersensitivity to telmisartan.
  • Women during the second and third trimesters of pregnancy.
  • Patients with severe hepatic impairment or biliary obstructive disorders.
  • Patients with diabetes mellitus who are concurrently taking an aliskiren-containing product.

Age-Related and Condition-Specific Eligibility

Population Group Eligibility Status (Regulatory Wording)
Pediatric (under 18 years) Use not recommended; safety and efficacy are not established.
Older Adults (65+ years) Approved for use; no dosage adjustment is typically necessary.
Severe Renal Impairment Limited experience is available; use requires special caution.
Mild to Moderate Hepatic Impairment Use with caution; a lower maximum dose may be applied.
Pregnancy/Lactation Contraindicated in later pregnancy and not recommended while breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define Telmisartan's interaction profile by specific contraindicated combinations and risks related to pharmacodynamic and pharmacokinetic effects.

Interaction Classifications (High-Level)

Classification Examples of Interacting Substances
Formally Contraindicated Aliskiren (in patients with diabetes mellitus), Sparsentan, Elagolix (due to OATP1B1 inhibition).
Pharmacodynamic Risk Potassium-Sparing Diuretics, Potassium Supplements, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), other RAS Inhibitors.
Exposure Modification Digoxin (plasma levels increased), Food (Telmisartan exposure reduced).

Official Interaction Statements

  • Co-administration with other RAS inhibitors (e.g., ACE inhibitors) carries a documented risk of hypotension, hyperkalemia, and changes in renal function due to dual blockade.
  • Co-use with potassium-containing substances increases the additive risk of hyperkalemia.
  • NSAIDs may attenuate the antihypertensive effect and increase the risk of renal function deterioration. This risk is specified as higher in elderly or renally compromised patients.
  • The systemic exposure of co-administered Digoxin is documented to be significantly increased. The administration of food is stated to reduce the bioavailability of Telmisartan.
  • The use of alcohol may increase the documented risk of dizziness.

Mechanism of Action

Mechanism of Action: Maxtel

Maxtel works by engaging the GABAergic system, the core inhibitory mechanism within the central nervous system ( CNS), to adjust neuronal activity. Its action is focused on molecular targets that govern the flux of ions across the cell membrane.


Positive Allosteric Modulation of GABA A Receptors

Maxtel acts as a positive allosteric modulator of GABA A receptors, enhancing the binding and inhibitory effects of the neurotransmitter GABA. This interaction increases the receptor's affinity for GABA, inducing an increase in the inhibitory postsynaptic potential.


Regulating Neuronal Chloride Ion ( Cl^-) Conductance

Receptor engagement results in the increased conductance of chloride ions ( Cl^-) across the neuronal membrane. This change in transmembrane ion potential leads to hyperpolarization, which decreases the neuron's threshold for action potential firing and results in a reduction of overall neuronal excitability.

Dosage and Administration Information

Official Administration Guidelines

Maxtel (Telmisartan) is exclusively for oral administration as a tablet and is typically used as part of a long-term treatment plan for chronic management. The medication is dosed once daily, a frequency pattern supported by its pharmacological properties, which promote sustained action. It may be taken with or without food, offering flexibility in routine use.

Standard Labeled Dosing

The standard starting dose for hypertension is 40 mg once daily, with the approved dosage range extending up to a maximum of 80 mg once daily. For the indication of cardiovascular risk reduction, the established daily dose is 80 mg. The maximal effect of the medication is typically attained within four to eight weeks of starting treatment, which informs the schedule for dose evaluation and any subsequent adjustments.

Population-Specific Constraints

Established instructions impose specific constraints for certain populations, defining the permissible daily dose. In patients with mild to moderate hepatic (liver) impairment, the total daily dose should not exceed 40 mg. While no initial adjustment is required for older adults, a lower starting dose of 20 mg may be considered for patients with severe renal (kidney) impairment or those undergoing haemodialysis. Use in the pediatric population (under 18 years) is not officially established.

Handling and Procedural Note

Due to the nature of the tablet, a specific handling constraint requires that Maxtel must be kept in the sealed blister pack and removed only immediately before the time of administration. If a dose is missed, it should not be doubled; instead, patients should resume the regular once-daily dosing schedule.

Recent Clinical Evidence

Research evidence / Overview of Studies for Maxtel


Evidence for use in Essential Hypertension (High Blood Pressure)

Clinical evaluation of Maxtel for managing high blood pressure primarily involves numerous Randomized Controlled Trials (RCTs). These short- to intermediate-term studies were designed to explore the relationship between the treatment and various blood pressure measurements, often comparing it to an inactive treatment or other standard blood pressure medications. Studies reported patterns showing the measurement of change in both Systolic and Diastolic Blood Pressure (SBP/DBP), tracking these values in the clinic and over a 24-hour period using Ambulatory Blood Pressure Monitoring (ABPM). While short-term blood pressure changes are well-documented, research exploring the long-term association between Maxtel and the incidence of clinical events solely in the non-high-risk hypertension population is less defined compared to the results from larger, longer-duration cardiovascular trials.


Evidence for use in Reducing Cardiovascular Risk

Beyond managing blood pressure, Maxtel has been evaluated in large, long-term, event-driven RCTs to assess its role in exploring the incidence of major cardiovascular events in high-risk adult populations (e.g., those with a history of stroke or myocardial infarction, or high-risk Type 2 Diabetes). The outcomes tracked were hard clinical events, including cardiovascular death, nonfatal stroke, and nonfatal heart attack. The trials reported findings describing the observed incidence of the composite cardiovascular endpoint in the Maxtel group relative to the active comparator group. The evidence structure is based on numerous multi-year trials, and the results reflect the specific high-risk populations studied.


Research on Related Renal and Metabolic Outcomes

Studies specifically investigated Maxtel in patients with Type 2 Diabetes Mellitus, focusing on research exploring the association between Maxtel and kidney function biomarkers. Research examined outcomes related to kidney health, specifically monitoring the Urinary Albumin-to-Creatinine Ratio (UACR), which is a specific physiological measurement used in the assessment of kidney status. Studies reported patterns of change in the measurement of albumin in the urine in the observed populations with Type 2 Diabetes. Data for these specific outcomes are still emerging compared to the core blood pressure and cardiovascular event data.


What is Still Uncertain About Maxtel

Research exploring a long-term association for Maxtel relative to other Angiotensin II Receptor Blockers (ARBs) for hard clinical outcomes is limited and findings were sometimes mixed across studies. Furthermore, appropriate studies have not been performed to establish the observed patterns or specific measurements in the pediatric population (children and adolescents). Finally, findings describe group patterns, and research does not offer personal predictions of outcome.

Key Studies & References

  1. Angiotensin-Converting Enzyme (ACE) Inhibitors (NIH overview, context for ARBs)
  2. Efficacy of telmisartan versus losartan on 24-h ambulatory blood pressure in patients with mild-to-moderate hypertension: a meta-analysis of randomized controlled trials

Frequently Asked Questions (FAQ)

Common questions about Maxtel (FAQ)


Q: How quickly can I expect to notice any effects from Maxtel?

Official product information indicates that the initial blood pressure-lowering effect may be seen within 3 hours after taking a single dose. However, the full or maximum effect of the medication is typically achieved after a few weeks, usually between four and eight weeks, of consistent treatment.


Q: Is Maxtel the same type of medicine as [similar drug name]?

Maxtel’s active ingredient, Telmisartan, belongs to a specific pharmacological class known as Angiotensin II Receptor Blockers (ARBs). Regulatory documents classify the drug based on its unique chemical structure and its precise way of targeting the AT1 receptor. This classification helps distinguish it from other types of blood pressure medications.


Q: What happens if I forget to take a dose of Maxtel?

Official guidance from regulatory bodies advises that a missed dose should not be doubled up to catch up. Instead, the patient should resume the regular once-daily dosing schedule as planned.


Q: Can Maxtel cause long-term health issues?

The official safety profile for Maxtel is based on data collected over several years in long-term clinical studies. These studies track the occurrence and frequency of adverse events during chronic use. This comprehensive information is regularly reviewed by regulatory authorities.


Q: Is it possible for Maxtel to stop working over time?

Clinical studies have examined the long-term consistency of Maxtel’s effects. Research findings indicate that the medication’s ability to lower blood pressure appeared to be maintained for up to at least one year during these long-term studies.


Q: Do I need to take Maxtel at the same time every day?

Regulatory information supports a once-daily dosing schedule, a pattern allowed by the drug’s pharmacological properties, specifically its terminal elimination half-life of approximately 24 hours. This long half-life supports a sustained effect over a full day.


Q: Does Maxtel interact with common pain relievers like ibuprofen?

Official documents describe that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), a class that includes ibuprofen, may potentially lessen the blood pressure-lowering effect of Maxtel. Additionally, co-use may increase the risk of worsening kidney function, particularly for elderly patients or those with existing kidney issues.


Q: How long does Maxtel usually stay in your system?

Based on pharmacokinetic data, the active ingredient in Maxtel is described as having a terminal elimination half-life of approximately 24 hours. This factor supports its use in a once-daily dosing regimen.


Q: Are there any studies comparing Maxtel to non-drug treatments?

The official regulatory documents primarily describe the results of Randomized Controlled Trials (RCTs) that compare Maxtel against an inactive substance (placebo) or other standard drug treatments. These trials assess the drug’s effects on blood pressure and cardiovascular outcomes.


Q: Is there a generic version of Maxtel available?

The active ingredient in Maxtel, Telmisartan, has been officially approved by regulatory bodies as a generic medication and may be available from various manufacturers.


Q: Can Maxtel affect my sleep?

The official adverse reaction list includes reports of psychiatric disorders, with documented events such as insomnia (difficulty sleeping) and somnolence (drowsiness) observed in clinical trials.


Q: Is it normal to feel a certain side effect when first starting Maxtel?

Official safety information notes that symptomatic hypotension (low blood pressure) may occur in some individuals, and this is sometimes noticed after the very first dose. This pattern is specified as being more common in patients who are dehydrated or have a salt deficiency.


Q: What is the difference between Maxtel and similar medicines mentioned online?

Maxtel is formally classified as an Angiotensin II Receptor Blocker (ARB), a specific type of medicine that targets the body's natural system for controlling blood vessel tension. Official documents detail that this precise, targeted mechanism is what defines its difference from other common classes of blood pressure medications.


Q: What are the serious, but rare, side effects of Maxtel?

The official safety profile includes events classified as rare (ge 1/10,000 to <1/1,000). Among these serious, but rare, reactions are reports of sepsis (severe blood poisoning, which can be fatal) and angioedema (swelling of the face, tongue, or throat, which can also be fatal).


Q: Does Maxtel interact with herbal supplements?

The interaction profile highlights risks from substances that can increase potassium levels in the blood, such as Potassium Supplements. Since many herbal products may also affect potassium, official warnings related to hyperkalemia (high potassium) may also apply.


Q: Does Maxtel interact with common vitamins?

Official documents detailing drug-drug and drug-food interactions focus on agents that affect blood pressure, potassium levels, or kidney function. There are no specific warnings in official labeling regarding interactions with common daily vitamins.


Q: Can I switch from a different medication to Maxtel?

Official dosage guidelines are provided for patients who may be transitioning from other medications. Regulatory approval allows the product to be used as a replacement or in combination therapy, indicating that formal protocols exist for making a change.


Q: What if I experience a rare or unexpected symptom while on Maxtel?

Official patient counseling materials advise contacting a healthcare provider for any unexpected side effects. Patients are informed that reporting mechanisms for side effects are available, such as directly to a relevant government health authority like the FDA (via MedWatch).


Q: Are the initial studies on Maxtel still considered relevant?

The current official labeling for Maxtel continues to cite and rely on the findings from the initial Randomized Controlled Trials (RCTs). These short- and long-term studies still form the essential evidence base supporting the drug's approved uses and safety profile.


Q: Is the onset time for Maxtel the same for every person?

The official documents describe the average timing for the onset of activity based on data collected from large groups in clinical trials. Scientific findings focus on describing group patterns, and research does not offer personal predictions of individual response or onset time.


Q: What should I know about drug class warnings that might apply to Maxtel?

As part of the Angiotensin II Receptor Blocker (ARB) class, official warnings address specific risks associated with this group of medications. These include risks related to fetal toxicity, low blood pressure (hypotension), and changes in kidney function.


Q: Can Maxtel be used with over-the-counter cold and flu medications?

Official warnings related to drug interactions highlight the potential risk with NSAIDs and other substances that may affect blood pressure or kidney function. Because many over-the-counter cold and flu products contain these or similar ingredients, they are subject to the same cautionary statements.


Q: Does Maxtel affect mood or mental state?

Official adverse event lists include reports of psychiatric disorders, with documented events such as anxiety, depression, and nervousness observed in clinical trials.


Q: Is there a maximum time frame for using Maxtel?

Maxtel is officially approved for the long-term treatment of essential hypertension and for the reduction of cardiovascular risk. The official labeling does not specify an absolute maximum duration of use for these chronic conditions.


Q: What is the typical duration of treatment with Maxtel?

The official documents characterize Maxtel as a medicine intended for use as part of a long-term treatment plan. Its primary uses, such as managing chronic hypertension and reducing cardiovascular risk, require ongoing, chronic administration.


Q: If I have kidney or liver issues, can I still use Maxtel?

Official documents state that the drug is contraindicated in severe liver impairment. For patients with kidney issues or mild-to-moderate liver issues, the use requires special caution, and regulatory documents indicate that specific dose limitations may be necessary.


Q: Can Maxtel affect my ability to drive or operate machinery?

The official safety profile notes that due to the potential risk of side effects such as dizziness or syncope (fainting), the medication may impair a person's ability to drive or safely operate machinery.


Q: What is the risk of dependence or addiction with Maxtel?

Official regulatory documents, which include a section on Drug Abuse and Dependence, provide a factual statement regarding the drug's established potential for abuse or dependence.


Q: Are there any specific laboratory tests required while taking Maxtel?

Official warnings advise that patients using Maxtel should have their blood pressure, renal function (kidney health), and electrolytes (like potassium) monitored closely. This is a standard measure for medications that affect the Renin-Angiotensin System.


How should Maxtel be stored and disposed of?

How to Store and Dispose of Maxtel?

The storage and handling of Maxtel (telmisartan) must adhere strictly to the official regulatory requirements to maintain the product's stability and integrity.

Official Storage Requirements

Requirement Official Rule
Temperature Store at temperatures not exceeding 30 C
Container Integrity Must remain in the original, sealed blister packaging
Handling Precaution Mandatory protection from moisture; do not remove tablets until immediately prior to use
Child Safety Keep the medicine out of the sight and reach of children

Disposal Instructions

Official labeling for this medicine dictates that disposal of any unused or expired tablets must be conducted according to local regulatory requirements. The product is not classified as a hazardous substance requiring special cytotoxic waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Maxtel found in:

A-Z Index: